Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Visionary Pharmaceuticals Awarded Phase 1 SBIR Grant

Published: Thursday, August 08, 2013
Last Updated: Thursday, August 08, 2013
Bookmark and Share
Company has been awarded grant to develop TH17 immunomodulators for inflammatory bowel disease.

Visionary Pharmaceuticals, Inc., has announced that the company has obtained a significant Phase 1 Small Business Innovation Research award “Development of RORγt Immunomodulators Targeting the TH17 Axis in IBD”.

The company is using the proceeds to develop novel small molecule retinoic acid related orphan receptor (ROR) modulators targeting TH17 T- lymphocytes in inflammatory bowel disease.

Visionary Pharmaceuticals has created an innovative drug discovery engine utilizing proprietary structure-based drug design technology to focus on nuclear hormone receptors.

The BindingSIGHTs platform encompasses an advanced suite of structural biology and chemical informatics computational tools.

BindingSIGHTs enables sophisticated in silico screening and structure-based drug design for molecular drug targets. With cell assays and deep expertise in nuclear receptor drug discovery Visionary Pharmaceuticals is currently developing several chemically diverse RORγt inverse agonists.

These compounds are potent, selective and demonstrate functional activity to ablate human TH17 differentiation and IL-17 cytokine secretion ex vivo.

“Nuclear hormone receptor modulators account for nearly 15% of all drugs sold in the US with $27 billion in annual sales. In this highly druggable class of targets RORγt inverse agonists represent a potential new source of blockbuster medications for significant unmet medical needs in autoimmune disease. With this grant we can now enable final optimization of our lead series as we move towards selection of an IND candidate.”, said Gordon Alton, Ph.D., President and CEO of Visionary.

Alton continued, “Obtaining this grant, especially under the current NIH budget pressures, reinforces the deep scientific credibility of our organization and rewards us for creating an innovative approach to treating inflammatory bowel disease.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
How to Control Shape, Structure of DNA and RNA
Researchers have used computational modelling to shed light on precisely how charged gold nanoparticles influence the structure of DNA and RNA.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos